Objective: Comparison of serum IL-6 levels in clinical stages Parkinson’s disease  patients with and without Сovid-19.

Background: Elevated levels of the cytokine IL-6 may indicate disease severity in patients with Parkinson’s disease (PD).

Method: Patients were divided into groups according to the clinical stages of the disease. When comparing the disease stages, 13 (28.9%) of patients in group 1 had stage 1, 14 (31.1%) had stage 2, 13 (28.9%) had stage 3, and 5 (11.1 %) are patients with stage 4 PD. The amount of IL-6 was checked using the IFA method.

Results: IL-6 in serum of patients with PD stage 1 in group 1 was 13.8±4.2, stage 2 patients were 21.8±5.1 pg/ml in serum and stage 3 was mixed 26 It was found to be .7±5.3 pg/ml pg/ml. The result of the comparison is that a reliable difference was observed between all stages of the disease, r≤0.001. When comparing disease stages of patients without Covid-19 in group 2, 12.1±5.2 pg/ml in stage 1, 16.45±4.8 pg/ml in stage 2, and 19.5±5.7 pg/ml was recorded, with a reliable difference compared to the control group, but no significant reliable difference was observed between the 1st and 2nd stages of the disease.

Conclusion: Covid-19 infection rapidly transforms disease stages in patients with PD, deepening from mild stages to severe stages. IL-6 is important in assessing the severity levels of PD patients with Covid-19 and requires a differential approach accordingly. Compared to the 1st stage, stage 2, stage 3 and stage 4 are more common when compared to the stages of the disease.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/levels-of-change-in-interleukin-6-levels-according-to-clinical-stages-of-parkinsons-disease-in-patients-with-and-without-covid-19/